PROCR and colorectal carcinoma: Despite this and previous reports highlighting links between EPCR and chemoresistance/chemosensitivity 6, 8, analysis of samples from the MRC COIN study did not reveal any association between EPCR expression and PFS in advanced CRC patients treated with chemotherapy, indicating that the impact of the EPCR‐high phenotype was insufficient to predict chemosensitivity in this setting, although we cannot exclude the possibility of relatively subtle effects beyond the power of our analysis.